The impact of 18F-deoxyglucose positron emission tomography on tumor staging, treatment strategy and treatment planning for radiotherapy in a department of radiation oncology

Pietro Gabriele, Giuseppe Malinverni, Gian Luca Moroni, Marco Gatti, Daniele Regge, Annibale Versari, Desiderio Serafini, Alessandro Fraternali, Diana Salvo

Research output: Contribution to journalArticle

Abstract

Aims and background: The study analyzed the potential contribution of positron emission tomography (PET) in patient selection for radiotherapy and in radiation therapy planning. Methods: Eighty-seven patients with a histological cancer diagnosis were accrued for the study from December 2000 to December 2001. Demographic characteristics included a median age of 54 years and male/female ratio of 51/36. All patients staged by conventional workup who were candidates for radiotherapy had PET imaging and were allocated to a conventional "pre/post-PET stage". The treatment protocol and the shape and/or size of the portals was directly related to PET results. We examined 26 lung cancers, 15 gastrointestinal tumors, 22 genitourinary cancers and 24 hematologic malignancies. Results: In the lung cancer group, the stage was modified in 10/26 patients (38.5%) by PET, with a change in management in 13 (50%) and a change in radiotherapy planning in 6 (23.1%). In the hematological group, stage was modified by PET in 8/24 cases (33.3%), with a change in treatment strategy in 9 (37.5%) and a change in radiotherapy planning in 3 (12.5%). In the gastrointestinal group, the stage was modified by PET in 2/15 cases (13.4%), with a change inn treatment strategy in 4 (26.7%) and a change in the decision for radiotherapy in 8 (no radiotherapy in 53.3%). In the mixed group (genitourinary, breast and other), the stage was modified by PET in 6/22 cases (27.3%), with a change in treatment strategy in 11 (50%) and a very low rate of change in radiotherapy planning. Conclusions: PET contributed to a modification of stage in 26/87 patients (30%), to a changing in treatment strategy in 37/87 (42.5%), and to a substantial change of the shape and/or size of radiotherapy portals in 13/43 (30%) who underwent radiotherapy.

Original languageEnglish
Pages (from-to)579-585
Number of pages7
JournalTumori
Volume90
Issue number6
Publication statusPublished - Nov 2004

Fingerprint

Radiation Oncology
Neoplasm Staging
Deoxyglucose
Positron-Emission Tomography
Radiotherapy
Therapeutics
Lung Neoplasms
Urogenital Neoplasms
Hematologic Neoplasms
Clinical Protocols
Patient Selection
Neoplasms
Breast
Demography

Keywords

  • Positron emission tomography
  • Radiotherapy treatment planning
  • Tumor staging

ASJC Scopus subject areas

  • Cancer Research

Cite this

The impact of 18F-deoxyglucose positron emission tomography on tumor staging, treatment strategy and treatment planning for radiotherapy in a department of radiation oncology. / Gabriele, Pietro; Malinverni, Giuseppe; Moroni, Gian Luca; Gatti, Marco; Regge, Daniele; Versari, Annibale; Serafini, Desiderio; Fraternali, Alessandro; Salvo, Diana.

In: Tumori, Vol. 90, No. 6, 11.2004, p. 579-585.

Research output: Contribution to journalArticle

@article{470639dd680a4b0cb34d205da8622f94,
title = "The impact of 18F-deoxyglucose positron emission tomography on tumor staging, treatment strategy and treatment planning for radiotherapy in a department of radiation oncology",
abstract = "Aims and background: The study analyzed the potential contribution of positron emission tomography (PET) in patient selection for radiotherapy and in radiation therapy planning. Methods: Eighty-seven patients with a histological cancer diagnosis were accrued for the study from December 2000 to December 2001. Demographic characteristics included a median age of 54 years and male/female ratio of 51/36. All patients staged by conventional workup who were candidates for radiotherapy had PET imaging and were allocated to a conventional {"}pre/post-PET stage{"}. The treatment protocol and the shape and/or size of the portals was directly related to PET results. We examined 26 lung cancers, 15 gastrointestinal tumors, 22 genitourinary cancers and 24 hematologic malignancies. Results: In the lung cancer group, the stage was modified in 10/26 patients (38.5{\%}) by PET, with a change in management in 13 (50{\%}) and a change in radiotherapy planning in 6 (23.1{\%}). In the hematological group, stage was modified by PET in 8/24 cases (33.3{\%}), with a change in treatment strategy in 9 (37.5{\%}) and a change in radiotherapy planning in 3 (12.5{\%}). In the gastrointestinal group, the stage was modified by PET in 2/15 cases (13.4{\%}), with a change inn treatment strategy in 4 (26.7{\%}) and a change in the decision for radiotherapy in 8 (no radiotherapy in 53.3{\%}). In the mixed group (genitourinary, breast and other), the stage was modified by PET in 6/22 cases (27.3{\%}), with a change in treatment strategy in 11 (50{\%}) and a very low rate of change in radiotherapy planning. Conclusions: PET contributed to a modification of stage in 26/87 patients (30{\%}), to a changing in treatment strategy in 37/87 (42.5{\%}), and to a substantial change of the shape and/or size of radiotherapy portals in 13/43 (30{\%}) who underwent radiotherapy.",
keywords = "Positron emission tomography, Radiotherapy treatment planning, Tumor staging",
author = "Pietro Gabriele and Giuseppe Malinverni and Moroni, {Gian Luca} and Marco Gatti and Daniele Regge and Annibale Versari and Desiderio Serafini and Alessandro Fraternali and Diana Salvo",
year = "2004",
month = "11",
language = "English",
volume = "90",
pages = "579--585",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - The impact of 18F-deoxyglucose positron emission tomography on tumor staging, treatment strategy and treatment planning for radiotherapy in a department of radiation oncology

AU - Gabriele, Pietro

AU - Malinverni, Giuseppe

AU - Moroni, Gian Luca

AU - Gatti, Marco

AU - Regge, Daniele

AU - Versari, Annibale

AU - Serafini, Desiderio

AU - Fraternali, Alessandro

AU - Salvo, Diana

PY - 2004/11

Y1 - 2004/11

N2 - Aims and background: The study analyzed the potential contribution of positron emission tomography (PET) in patient selection for radiotherapy and in radiation therapy planning. Methods: Eighty-seven patients with a histological cancer diagnosis were accrued for the study from December 2000 to December 2001. Demographic characteristics included a median age of 54 years and male/female ratio of 51/36. All patients staged by conventional workup who were candidates for radiotherapy had PET imaging and were allocated to a conventional "pre/post-PET stage". The treatment protocol and the shape and/or size of the portals was directly related to PET results. We examined 26 lung cancers, 15 gastrointestinal tumors, 22 genitourinary cancers and 24 hematologic malignancies. Results: In the lung cancer group, the stage was modified in 10/26 patients (38.5%) by PET, with a change in management in 13 (50%) and a change in radiotherapy planning in 6 (23.1%). In the hematological group, stage was modified by PET in 8/24 cases (33.3%), with a change in treatment strategy in 9 (37.5%) and a change in radiotherapy planning in 3 (12.5%). In the gastrointestinal group, the stage was modified by PET in 2/15 cases (13.4%), with a change inn treatment strategy in 4 (26.7%) and a change in the decision for radiotherapy in 8 (no radiotherapy in 53.3%). In the mixed group (genitourinary, breast and other), the stage was modified by PET in 6/22 cases (27.3%), with a change in treatment strategy in 11 (50%) and a very low rate of change in radiotherapy planning. Conclusions: PET contributed to a modification of stage in 26/87 patients (30%), to a changing in treatment strategy in 37/87 (42.5%), and to a substantial change of the shape and/or size of radiotherapy portals in 13/43 (30%) who underwent radiotherapy.

AB - Aims and background: The study analyzed the potential contribution of positron emission tomography (PET) in patient selection for radiotherapy and in radiation therapy planning. Methods: Eighty-seven patients with a histological cancer diagnosis were accrued for the study from December 2000 to December 2001. Demographic characteristics included a median age of 54 years and male/female ratio of 51/36. All patients staged by conventional workup who were candidates for radiotherapy had PET imaging and were allocated to a conventional "pre/post-PET stage". The treatment protocol and the shape and/or size of the portals was directly related to PET results. We examined 26 lung cancers, 15 gastrointestinal tumors, 22 genitourinary cancers and 24 hematologic malignancies. Results: In the lung cancer group, the stage was modified in 10/26 patients (38.5%) by PET, with a change in management in 13 (50%) and a change in radiotherapy planning in 6 (23.1%). In the hematological group, stage was modified by PET in 8/24 cases (33.3%), with a change in treatment strategy in 9 (37.5%) and a change in radiotherapy planning in 3 (12.5%). In the gastrointestinal group, the stage was modified by PET in 2/15 cases (13.4%), with a change inn treatment strategy in 4 (26.7%) and a change in the decision for radiotherapy in 8 (no radiotherapy in 53.3%). In the mixed group (genitourinary, breast and other), the stage was modified by PET in 6/22 cases (27.3%), with a change in treatment strategy in 11 (50%) and a very low rate of change in radiotherapy planning. Conclusions: PET contributed to a modification of stage in 26/87 patients (30%), to a changing in treatment strategy in 37/87 (42.5%), and to a substantial change of the shape and/or size of radiotherapy portals in 13/43 (30%) who underwent radiotherapy.

KW - Positron emission tomography

KW - Radiotherapy treatment planning

KW - Tumor staging

UR - http://www.scopus.com/inward/record.url?scp=14244255982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244255982&partnerID=8YFLogxK

M3 - Article

C2 - 15762360

AN - SCOPUS:14244255982

VL - 90

SP - 579

EP - 585

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -